Moreover, our result showed that the number of overexpressed NKG2D ligands had no impact on clinical outcomes, although several studies showed that ULBP overexpression could predict better prognosis in patients with breast cancer [12], cervical cancer [13], and hepatocellular carcinoma [14, 15]. The gene discussed is KLRK1; the disease is hepatocellular carcinoma.